ChipScreen
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ChipScreen - overview
Established
2001
Location
Shenzhen, Guangdong, China
Primary Industry
Pharmaceuticals
About
ChipScreen, founded in 2001 and based in Shenzhen, China, is a biotech company that specializes in the research & development of small molecule pharmaceuticals. The company's founder, Chairman and Managing Director, Xianping Lu, has a PhD from Peking Union Medical College and was formerly the Director of R&D at Galderma S. A. 's North American R&D Center.
The company has applied for more than 680 invention patents and has been authorized more than 200. The company was listed on the IPO in 2019. The company’s main business is the research and development of small molecule drugs. The company’s self - developed products include Chidamide, Chiglitazar, and Cirotinib.
Its products are used in the fields of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and antiviral treatment. The company generates revenue by providing innovative small molecule drugs.
Current Investors
Lilly Asia Ventures, Hidea Investment, Richland Equities
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.chipscreen.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
ChipScreen - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 85,364,443.6 | 110,503,440.2 | 147,688,982.2 | 173,800,400.6 | 269,469,784.7 | 430,449,990.6 | - | - | - |
| % Revenue Growth (YoY) | - | 29.4% | 33.7% | 17.7% | 55.0% | 59.7% | - | - | - |
| EBITDA (USD) | 12,316,600 | 30,064,200 | 37,640,800 | 17,007,111.9 | 35,770,068.8 | 35,892,082.2 | - | - | - |
| Operating Income (USD) | 2,028,323.3 | 24,535,680.7 | 32,639,950.3 | 11,916,127.8 | 23,972,739.2 | 22,260,108.6 | - | - | - |
| Operating Margin | 2.4% | 22.2% | 22.1% | 6.9% | 8.9% | 5.2% | - | - | - |
| % EBITDA Margin | 14.4% | 27.2% | 25.5% | 9.8% | 13.3% | 8.3% | - | - | - |
| NET Income (USD) | 5,244,319.7 | 24,073,891.3 | 31,164,800 | 19,421,886.4 | 31,045,971.9 | 21,958,284.6 | - | - | - |
| % Net Margin | 6.1% | 21.8% | 21.1% | 11.2% | 11.5% | 5.1% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.